Monoclonal Antibody to HLA Class II Histocompatibility Antigen, DRB1 Beta Chain (HLA-DRB1)
Code | Size | Price |
---|
MAC167Hu23-20ul | 20uL | £93.00 |
Quantity:
MAC167Hu23-100ul | 100ul | £177.00 |
Quantity:
MAC167Hu23-200ul | 200ul | £239.00 |
Quantity:
MAC167Hu23-1ml | 1ml | £553.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1 Kappa
Antibody Clonality: Monoclonal
Antibody Clone: D2
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
HLA-DRB1; MHCDRb1; HLADRb1; Major Histocompatibility Complex Class II DR Beta 1; HLA Class II Histocompatibility Antigen,DRB1-9 Beta Chain; HLA class II histocompatibility antigen, DRB1-15 beta chain
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
HLA Class II Histocompatibility Antigen, DRB1 Beta Chain
Potency (Clone Number):
D2
Reactivity:
Po;
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;<br/>Immunohistochemistry: 5-20ug/mL;<br/>Immunocytochemistry: 5-20ug/mL;<br/>Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Major Histocompatibility Complex Class II DR Beta 1 (MHCDRb1) | RPC167Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||